The National Institute of Mental Health (NIMH) awarded a $440,092 Project Grant (CFDA 93.242 - Mental Health Research Grants) to OUI Therapeutics Inc. to develop and evaluate a novel digital therapeutic for the treatment of post-traumatic stress disorder (PTSD) in adults. The project, titled "DEVELOPMENT AND EVALUATION OF A NOVEL DIGITAL THERAPEUTIC FOR ADULTS WITH POST-TRAUMATIC STRESS DISORDER", aims to create a mobile app-based digital therapeutic called OTX-601. During Phase I, the company will develop the app, determine the optimal dose, and assess the feasibility, acceptability, and usability of OTX-601. They will also conduct a pilot randomized controlled trial to evaluate the preliminary efficacy of the digital therapeutic in treating PTSD. In Phase II, a larger randomized controlled trial will be conducted to determine the effectiveness of OTX-601 in treating PTSD. The award period is from June 5, 2024 to May 31, 2026.
Generated 1/28/25, 10:36 AM